Ibritumomab Tiuxetan

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

V10XX02

CAS registry number (Chemical Abstracts Service)

0206181-63-7

Chemical Formula

C6382-H9830-N1672-O1979-S54

Molecular Weight

143376

Therapeutic Categories

Antineoplastic agent

Immunomodulator

Chemical Name

Immunoglobulin G1, anti-(human CD20 (antigen)) (mouse monoclonal IDEC-Y2B8 gamma1-chain), disulfide with mouse monoclonal IDEC-Y2B8 kappa 63-chain, dimer, N-[2-bis-(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-N-[2-[bis(carboxymethyl)- amino]pro (WHO)

Foreign Names

• Ibritumomabum Tiuxetanum (Latin)
• Ibritumomab Tiuxetan (German)
• Ibritumomab Tiuxétan (French)
• Ibritumomab Tiuxetán (Spanish)

Generic Names

• Ibritumomab Tiuxetan (OS: USAN, BAN)
• IDEC 129 (IS: IDEC)
• IDEC Y2B8 (IS: IDEC)

Brand Names

• Zevalin Indium
  Bayer Yakuhin, Japan



• Zevalin Yttrium
  Bayer Yakuhin, Japan



• Zevalin
  Bayer, Belgium; Bayer, Canada; Bayer, Switzerland; Bayer, Germany; Bayer, United Kingdom; Bayer, Croatia (Hrvatska); Bayer, Sweden; Bayer, Turkey; Bayer Schering, Austria; Bayer Schering, Finland; Bayer Schering, France; Bayer Schering, Netherlands; Bayer Schering, South Africa; Bayer Schering Pharma, Norway; Biogen, United States; Pfizer, Israel; Schering, Hungary; Schering, Ireland; Schering, Italy; Schering, Luxembourg; Schering, Poland; Schering, Romania; Schering, Slovenia



• Zevamab
  Schering, Argentina

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.